C18:2 cis-9, trans-11; trans-10,cis-12 (1:1) |
Decrease in breast tumor development |
[50,51] |
Increased antioxidant activity |
[50] |
Inhibitory effects on various types of cancer, such as breast, skin, stomach, intestinal, and ovarian |
[52,53] |
Immunoregulatory effects |
[18] |
Decrease in body fat mass |
[17,54,55,56,57] |
Decreased sagittal abdominal diameter (cm) |
[58] |
Modulation of the inflammatory response |
[59,60] |
Increased lean body mass |
[55,61] |
Decreased glucose levels |
[14] |
Decrease in body fat mass in specific region (legs) |
[61] |
Decreased waist-hip ratio |
[61] |
C18:2 cis-9, trans-11 |
Positive influence on biochemical markers associated with Alzheimer’s disease |
[62,63] |
Anti-osteoporotic effects |
[16] |
Anti-atherosclerotic effects |
[15] |
C18:2 trans-10, cis-12 |
Inhibitory effects on the development of ovarian cancer |
[13] |
Inhibitory effects on prostate cancer |
[53] |